NCT04077255

EGFR-targeted Therapy for Gastric Cancer

Anti-EGFR Antibody (GC-1118) in Combination With Weekly Paclitaxel as a Second-line Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas With Amplifications

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 19 (estimated)
• Sponsor: National Cancer Center, Korea · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.

Detailed description

Participants will receive each treatment if the gastric cancer tissue sample reveals either EGFR gene amplification or strong (3+ or 2+) EGFR immunostaining

Conditions

• Adenocarcinoma of the Stomach

Interventions

Type	Name	Description
DRUG	Anti-EGFR antibody in combination with weekly paclitaxel	Intravenous GC-1118 in combination with weekly paclitaxel for EGFR-amplified cancer cancers as a second-line therapy

Timeline

• Start date: 2019-09-01
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2019-09-04
• Last updated: 2022-11-30

Locations

1 site across 1 country: South Korea